Business Description
Janux Therapeutics Inc
NAICS : 325412
SIC : 2834
11099 N. Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Description
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2360.78 | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 28.16 | |||||
| Beneish M-Score | 7.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.26 | |||||
| 9-Day RSI | 53.89 | |||||
| 14-Day RSI | 52.72 | |||||
| 6-1 Month Momentum % | -18.54 | |||||
| 12-1 Month Momentum % | -64.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 29.14 | |||||
| Quick Ratio | 29.14 | |||||
| Cash Ratio | 28.86 | |||||
| Days Sales Outstanding | 219.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -911.82 | |||||
| Net Margin % | -903.8 | |||||
| ROE % | -14.93 | |||||
| ROA % | -13.62 | |||||
| ROIC % | -515.65 | |||||
| ROC (Joel Greenblatt) % | -3592.57 | |||||
| ROCE % | -14.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 90.46 | |||||
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 1.61 | |||||
| EV-to-EBIT | -4.9 | |||||
| EV-to-EBITDA | -4.92 | |||||
| EV-to-Revenue | 44.39 | |||||
| EV-to-Forward-Revenue | 135.37 | |||||
| EV-to-FCF | -5.92 | |||||
| Price-to-Net-Current-Asset-Value | 1.63 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | -20.41 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:JANX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.846 | ||
| EPS (TTM) ($) | -1.53 | ||
| Beta | 0 | ||
| Volatility % | 67.92 | ||
| 14-Day RSI | 52.72 | ||
| 14-Day ATR ($) | 1.393003 | ||
| 20-Day SMA ($) | 14.184 | ||
| 12-1 Month Momentum % | -64.02 | ||
| 52-Week Range ($) | 9.39 - 35.8 | ||
| Shares Outstanding (Mil) | 41.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Janux Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||